+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cystic Fibrosis Therapeutics Market Report by Drug Class, Route of Administration, Distribution Channel, Regions and Company Analysis 2024-2032

  • PDF Icon

    Report

  • 220 Pages
  • June 2024
  • Region: Global
  • Renub Research
  • ID: 5715846
Cystic Fibrosis Therapeutics Market share is anticipated to be about US$ 15.42 billion by 2032. The CAGR for the market from 2024 to 2032 is 9.05%. According to the publisher, it was valued US$ 7.07 billion in 2023.

A genetic condition known as cystic fibrosis (CF) results in an accumulation of thick, sticky mucus in the organs, obstructing and harming them. Because CF affects the lungs and airways, which can make breathing difficult and lead to frequent infections, many people consider it to be a lung illness. However, because it also results in pancreatic cysts and scarring (fibrosis), it is also known as cystic fibrosis. It may be difficult to extract nutrients from the digestive tract due to duct blockages caused by this damage and the thick mucus that releases digesting enzymes. The liver, sinuses, intestines, and sex organs can all be impacted by CF. Cystic fibrosis is a congenital condition. It is a chronic condition that worsens with time. Most CF patients do not live as long as those without the disease.
  • Approximately 70,000 people worldwide suffer with cystic fibrosis (CF), one of the most prevalent hereditary disorders, according to the NIH.

Cystic Fibrosis Therapeutics Market Growth Opportunities

  • The growing prevalence of cystic fibrosis (CF) is one of the key factors driving the cystic fibrosis therapeutics market over the forecast period.
  • The CF Foundation said that approximately 40,000 adults and children in the US have cystic fibrosis, and 105,000 people worldwide are thought to have received a CF diagnosis.
  • Growing awareness of this degenerative genetic illness and the growing use of pharmaceutical therapy are the also the factors driving the cystic fibrosis therapeutics industry.
  • For instance- The cystic fibrosis community gathers for CF Awareness Month in May. "Resilient" is this year's CF Awareness Month theme. Regardless of people’s relationship to cystic fibrosis, the Cystic Fibrosis Foundation offers shareable resources to assist them in sharing their story on social media this month and throughout the year.
  • The market for cystic fibrosis therapeutics is expanding thanks to the numerous advances in cystic fibrosis pharmacotherapy. The other elements anticipated to propel the cystic fibrosis therapeutics market in the next years are also an increase in R&D investment and legislation that is supportive of the industry.
  • In March 2023 - To speed up the development of novel medicines for cystic fibrosis patients, LifeArc, a member of the CF AMR Syndicate, is offering drug discovery innovators £3 million in joint funding. About five collaborative initiatives that seek to quickly discover novel antimicrobial medicines to treat chronic respiratory infections in individuals with cystic fibrosis will be supported by the CF AMR Syndicate's Collaborative Discovery Programme.

Asia-Pacific Cystic Fibrosis Therapeutics Market

  • Both the number of patients and the popularity of the urban lifestyle are rising in the area. This is anticipated to drive the cystic fibrosis therapeutics market in Asia-Pacific.
  • According to the NIH, China has been steadily recognizing cystic fibrosis (CF) in recent years. The number of CF patients reported in China in the last ten years is more than 2.5 times the total number in the preceding thirty years, and the projected total number of CF patients in China is more than 20 000.
  • According to a research released by four United Nations organizations, Asia's cities are expanding so quickly that by 2030, over half of the vast population of the region is predicted to live in urban settings. This will have similarly significant effects on urban food security and nutrition.
  • Rising healthcare expenditures are anticipated to fuel the cystic fibrosis treatment market in the Asia-Pacific region.
  • Asia-Pacific will have the highest growth in healthcare spending, making up over 20% of global spending by 2030, predicts Bain & Company. Customers are willing to spend more and take a more proactive role in maintaining their health. In exchange for improved health outcomes, better experiences, and greater efficiency, about 50% of all consumers - 58% of whom are Gen Z - plan to increase their healthcare spending.
  • Increased funding for CF pharmaceutical research and development studies, along with other helpful government initiatives, will propel the growth of the Asia-Pacific cystic fibrosis medicines market.
  • In February 2023 - An international patient-led movement has been launched in several nations, including India, to gain access to Vertex Pharmaceuticals' (American biotech business) Trikafta, a treatment for cystic fibrosis (CF).

Cystic Fibrosis Therapeutics Industry News

Leading companies in the Cystic Fibrosis Therapeutics Industry are Novartis AG, Pfizer, AstraZeneca, Vertex Pharmaceuticals, Abbvie Inc., Gilead Sciences, and Viatris INC.
  • In March 2024 - Israeli business BiomX purchased American startup Adaptive Phage Therapeutics to establish a biotech company dedicated on advancing two genetically modified viruses that eradicate bacteria through clinical trials.
  • In November 2023 - Arcturus Therapeutics's ARCT-032 has been designated as an orphan drug by the US Food and medication Administration (FDA) to treat cystic fibrosis (CF).
  • In November 2023 - The licenses for the cystic fibrosis medications Kaftrio (ivacaftor, tezacaftor, and elexacaftor) and Kalydeco (ivacaftor) for children two to five years old have been renewed by the Medicines and Healthcare Products Regulatory Agency (MHRA).
  • In October 2023 - ATUM has extended its collaboration with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical enterprise committed to enhancing the quality of life for individuals afflicted with cystic fibrosis (CF) and other uncommon illnesses. The extended collaboration comes after a fruitful collaboration that expedited the introduction of ANG003 into a clinical trial that was just started in individuals with cystic fibrosis.
  • In May 2023- Tavanta Therapeutics at Two Renowned Scientific Conferences Released New Preclinical Data for Their Cystic Fibrosis Candidate, TAVT-135.
  • In April 2023 - The previously disclosed merger of Vallon Pharmaceuticals, Inc. (now GRI Bio, Inc.) and GRI Bio, Inc. has been completed. The united business will be known as "GRI Bio, Inc." and its primary goal will be to further GRI Bio's cutting-edge NKT cell modulator pipeline for the management of autoimmune, fibrotic, and inflammatory illnesses.

Drug Class

1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
2. Bronchodilators
3. Mucolytic
4. Pancreatic Enzyme Supplement
5. Others

Route of Administration

1. Oral Drugs
2. Inhaled Drugs

Distribution Channel

1. Hospitals
2. Retail Pharmacies
3. Others

Countries

1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

All the Key players have been covered from 4 Viewpoints:

  • Business overview
  • Recent Development
  • SWOT Analysis
  • Revenue Analysis

Key Players Analysis

1. Vertex Pharmaceuticals
2. Abbvie Inc.
3. Novartis Ag
4. Gilead Sciences
5. Viatris INC
6. Pfizer
7. Astrazeneca
8. F. Hoffmann-La Roche Ltd

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenge
5. Global Cystic Fibrosis Therapeutics Market
6. Market Share - Global Cystic Fibrosis Therapeutics
6.1 By Drugs Type
6.2 By Route of Administration
6.3 By Distribution Channel
6.4 By Countries
7. Drug Class - Global Cystic Fibrosis Therapeutics Market
7.1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
7.2 Bronchodilators
7.3 Mucolytic
7.4 Pancreatic Enzyme Supplement
7.5 Others
8. Route of Administration - Global Cystic Fibrosis Therapeutics Market
8.1 Oral Drugs
8.2 Inhaled Drugs
9. Distribution Channel - Global Cystic Fibrosis Therapeutics Market
9.1 Hospitals
9.2 Retail Pharmacies
9.3 Others
10. Countries - Global Cystic Fibrosis Therapeutics Market
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherland
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa
11. Porter’s Five Forces Analysis - Global Cystic Fibrosis Therapeutics Market
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis - Global Cystic Fibrosis Therapeutics Market
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Cystic Fibrosis Drugs Insights
13.1 Marketed Drugs
13.1.1 TRIKAFTA: Vertex Pharmaceuticals
13.1.1.1 Product description
13.1.1.2 Clinical trial & development
13.1.1.3 Safety and efficacy
13.1.2 SYMDEKO: Vertex Pharmaceuticals
13.1.2.1 Product description
13.1.2.2 Clinical trial & development
13.1.2.3 Safety and efficacy
13.1.3 ORKAMBI: Vertex Pharmaceuticals
13.1.3.1 Product description
13.1.3.2 Clinical trial & development
13.1.3.3 Safety and efficacy
13.1.4 KALYDECO: Vertex Pharmaceuticals
13.1.4.1 Product description
13.1.4.2 Clinical trial & development
13.1.4.3 Safety and efficacy
13.2 Emerging Drugs
13.2.1 Ensifentrine: Verona Pharmaceuticals
13.2.1.1 Product description
13.2.1.2 Clinical trial & development
13.2.1.3 Safety and Efficacy
13.2.2 ELX-02: Eloxx Pharmaceuticals, Inc.
13.2.2.1 Product description
13.2.2.2 Clinical trial & development
13.2.2.3 Safety and Efficacy
13.2.3 VX-121/TEZ/ VX-561: Vertex Pharmaceuticals
13.2.3.1 Product description
13.2.3.2 Clinical trial & development
13.2.3.3 Safety and Efficacy
13.2.4 POL6014 (Lonodelestat): Santhera Pharmaceuticals
13.2.4.1 Product description
13.2.4.2 Clinical trial & development
13.2.4.3 Safety and Efficacy
13.2.5 LAU-7b: Laurent Pharmaceuticals Inc.
13.2.5.1 Product description
13.2.5.2 Clinical trial & development
13.2.5.3 Safety and Efficacy
14. Key Players Analysis
14.1 Vertex Pharmaceuticals
14.1.1 Business overview
14.1.2 Key Persons
14.1.3 Recent Development
14.1.4 SWOT Analysis
14.1.5 Revenue Analysis
14.2 Abbvie Inc.
14.2.1 Business overview
14.2.2 Key Persons
14.2.3 Recent Development& Strategies
14.2.4 SWOT Analysis
14.2.5 Revenue Analysis
14.3 Novartis Ag
14.3.1 Business overview
14.3.2 Key Persons
14.3.3 Recent Development
14.3.4 SWOT Analysis
14.3.5 Revenue Analysis
14.4 Gilead Sciences
14.4.1 Business overview
14.4.2 Key Persons
14.4.3 Recent Development
14.4.4 SWOT Analysis
14.4.5 Revenue Analysis
14.5 Viatris INC
14.5.1 Business overview
14.5.2 Key Persons
14.5.3 Recent Development
14.5.4 SWOT Analysis
14.5.5 Revenue Analysis
14.6 Pfizer
14.6.1 Business overview
14.6.2 Key Persons
14.6.3 Recent Development
14.6.4 SWOT Analysis
14.6.5 Revenue Analysis
14.7 Astrazeneca
14.7.1 Business overview
14.7.2 Key Persons
14.7.3 Recent Development
14.7.4 SWOT Analysis
14.7.5 Revenue Analysis
14.8 F. Hoffmann-La Roche Ltd
14.8.1 Business overview
14.8.2 Key Persons
14.8.3 Recent Development
14.8.4 SWOT Analysis
14.8.5 Revenue Analysis

Companies Mentioned

  • Vertex Pharmaceuticals
  • Abbvie Inc.
  • Novartis Ag
  • Gilead Sciences
  • Viatris INC
  • Pfizer
  • Astrazeneca
  • F. Hoffmann-La Roche Ltd

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information